Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B1962 in advanced solid tumors
NCT05650385Phase 1Not yet recruiting
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of B1962 in solid tumor (10 cohorts), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoints: Dose Limiting Toxicity, Adverse Event Assessment and 4 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
B1962
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05650385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650385.